New York, NY Clinical Trials Report — April 2026

For New Yorkers considering participation in clinical research, April 2026 brings a crucial period for those looking to join studies before enrollment closes. Across New York City, 243 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 47 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, neurological conditions, and cardiovascular health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (9 trials)
• Prostate cancer (4 trials)
• Glioblastoma (4 trials)
• Major depressive disorder (4 trials)
• Myelodysplastic syndromes (3 trials)
• Parkinson disease (3 trials)
• Osteoarthritis, knee (3 trials)
• Head and neck squamous cell carcinoma (3 trials)
• Colorectal cancer (3 trials)
• Heart failure (3 trials)

This month, New York City saw the opening of 25 new clinical trials, a decrease from the 46 trials that launched in March 2026. Despite this dip in new openings, the city continues to be a vibrant hub for medical research, with a total of 3,123 clinical trials currently recruiting across 1,302 research facilities.

Spotlight on New Research Opportunities

April brings several high-profile new trials to New York, NY, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Memorial Sloan Kettering Cancer Center is sponsoring NCT07507643, "A Study of Methylprednisolone in People Having Liver Surgery." This Phase 3 study, aiming for 750 participants, investigates whether methylprednisolone administered before surgery can reduce side effects like infections and shorten hospital stays.
• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy.
• Novo Nordisk A/S is initiating NCT07509307, "AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain." This Phase 3 study, designed for 400 participants, will compare the safety and effect of NNC0487-0111, administered as a weekly injection, against a placebo.
• Caliway Biopharmaceuticals Co., Ltd. is sponsoring NCT07526974, "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )." This Phase 3, randomized, double-blinded, placebo-controlled study will evaluate CBL-514 injection for reducing abdominal subcutaneous fat in 320 participants.
• Columbia University is leading NCT07511621, "A Multi-Level Strategy for De-implementing Mammography Overuse Among Older Women." This project, involving 500 participants, aims to reduce the overuse of screening mammography in women aged 75 years and older.
• A registry study, NCT07535268, "REPRESENT-PF Registry," sponsored by Vivek Reddy, will evaluate the safety and effectiveness of Pulsed Field Ablation (PFA) for atrial fibrillation in underrepresented minority patients, aiming for 275 participants.

New trials this month are exploring a range of conditions, including non-small cell lung cancer, leiomyosarcoma, central centrifugal cicatricial alopecia, diffuse pleural mesothelioma, frontal fibrosing alopecia, gastroesophageal carcinoma, and a study specifically for healthy volunteers. Drug trials account for the majority of new studies, with 15 new drug trials, followed by 5 device trials and 4 behavioral trials.

For individuals without a specific medical condition, there are significant opportunities to contribute. 6 of the new trials launched this month are actively seeking healthy volunteers. Across New York City, a total of 374 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

New York City's Research Hubs

New York City is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Memorial Sloan Kettering Cancer Center (467 trials)
• NYU Langone Health (240 trials)
• Icahn School of Medicine at Mount Sinai (222 trials)
• Columbia University Irving Medical Center (162 trials)
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) (134 trials)
• Columbia University Medical Center (124 trials)
• Mount Sinai Hospital (116 trials)
• Weill Cornell Medicine (114 trials)
• Columbia University (101 trials)
• Research Site (77 trials)
• Laura and Isaac Perlmutter Cancer Center at NYU Langone (65 trials)
• Hospital for Special Surgery (62 trials)

These institutions offer a broad spectrum of research, from oncology at Memorial Sloan Kettering and NYU Langone's Perlmutter Cancer Center, to diverse medical fields at NYU Langone Health, Icahn School of Medicine at Mount Sinai, and Columbia University's medical centers.

Broadening Your Search: Nearby Options

While New York City offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within New York State. Cities with active trials include Harrison (5 trials), Commack (5 trials), The Bronx (4 trials), Brooklyn (2 trials), Rochester (2 trials), Rockville Centre (2 trials), Syracuse (2 trials), and Uniondale (2 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 25 new trials launched this month, 21 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials are specifically designed for female participants. Academic institutions continue to play a vital role in New York City's research ecosystem, with Memorial Sloan Kettering Cancer Center, NYU Langone Health, Weill Medical College of Cornell University, Icahn School of Medicine at Mount Sinai, and Hospital for Special Surgery, New York sponsoring the majority of new trials. Industry sponsors like Bayer, Incyte Corporation, and Jazz Pharmaceuticals are also driving significant research efforts.

As we move into the spring, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the continued exploration of new therapeutic strategies, with New York City's robust research community at the forefront of medical innovation.